Tags

Type your tag names separated by a space and hit enter

Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
J Aerosol Med Pulm Drug Deliv. 2014 Apr; 27(2):81-93.JA

Abstract

BACKGROUND

The purpose was to design and characterize inhalable microparticulate/nanoparticulate dry powders of mannitol with essential particle properties for targeted dry powder delivery for cystic fibrosis mucolytic treatment by dilute organic solution spray drying, and, in addition, to tailor and correlate aerosol dispersion performance delivered as dry powder inhalers based on spray-drying conditions and solid-state physicochemical properties.

METHODS

Organic solution advanced spray drying from dilute solution followed by comprehensive solid-state physicochemical characterization and in vitro dry powder aerosolization were used.

RESULTS

The particle size distribution of the spray-dried (SD) powders was narrow, unimodal, and in the range of ∼500 nm to 2.0 μm. The particles possessed spherical particle morphology, relatively smooth surface morphology, low water content and vapor sorption (crystallization occurred at exposure above 65% relative humidity), and retention of crystallinity by polymorphic interconversion. The emitted dose, fine particle fraction (FPF), and respirable fraction (RF) were all relatively high. The mass median aerodynamic diameters were below 4 μm for all SD mannitol aerosols.

CONCLUSION

The in vitro aerosol deposition stage patterns could be tailored based on spray-drying pump rate. Positive linear correlation was observed between both FPF and RF values with spray-drying pump rates. The interplay between various spray-drying conditions, particle physicochemical properties, and aerosol dispersion performance was observed and examined, which enabled tailoring and modeling of high aerosol deposition patterns.

Authors+Show Affiliations

1 University of Kentucky College of Pharmacy , Department of Pharmaceutical Sciences-Drug Development Division, Lexington, KY 40536-0596.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24502451

Citation

Li, Xiaojian, et al. "Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-dried Microparticulate/nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers." Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 27, no. 2, 2014, pp. 81-93.
Li X, Vogt FG, Hayes D, et al. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2014;27(2):81-93.
Li, X., Vogt, F. G., Hayes, D., & Mansour, H. M. (2014). Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 27(2), 81-93. https://doi.org/10.1089/jamp.2013.1078
Li X, et al. Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-dried Microparticulate/nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2014;27(2):81-93. PubMed PMID: 24502451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. AU - Li,Xiaojian, AU - Vogt,Frederick G, AU - Hayes,Don,Jr AU - Mansour,Heidi M, Y1 - 2014/02/06/ PY - 2014/2/8/entrez PY - 2014/2/8/pubmed PY - 2015/4/10/medline SP - 81 EP - 93 JF - Journal of aerosol medicine and pulmonary drug delivery JO - J Aerosol Med Pulm Drug Deliv VL - 27 IS - 2 N2 - BACKGROUND: The purpose was to design and characterize inhalable microparticulate/nanoparticulate dry powders of mannitol with essential particle properties for targeted dry powder delivery for cystic fibrosis mucolytic treatment by dilute organic solution spray drying, and, in addition, to tailor and correlate aerosol dispersion performance delivered as dry powder inhalers based on spray-drying conditions and solid-state physicochemical properties. METHODS: Organic solution advanced spray drying from dilute solution followed by comprehensive solid-state physicochemical characterization and in vitro dry powder aerosolization were used. RESULTS: The particle size distribution of the spray-dried (SD) powders was narrow, unimodal, and in the range of ∼500 nm to 2.0 μm. The particles possessed spherical particle morphology, relatively smooth surface morphology, low water content and vapor sorption (crystallization occurred at exposure above 65% relative humidity), and retention of crystallinity by polymorphic interconversion. The emitted dose, fine particle fraction (FPF), and respirable fraction (RF) were all relatively high. The mass median aerodynamic diameters were below 4 μm for all SD mannitol aerosols. CONCLUSION: The in vitro aerosol deposition stage patterns could be tailored based on spray-drying pump rate. Positive linear correlation was observed between both FPF and RF values with spray-drying pump rates. The interplay between various spray-drying conditions, particle physicochemical properties, and aerosol dispersion performance was observed and examined, which enabled tailoring and modeling of high aerosol deposition patterns. SN - 1941-2703 UR - https://www.unboundmedicine.com/medline/citation/24502451/Design_characterization_and_aerosol_dispersion_performance_modeling_of_advanced_spray_dried_microparticulate/nanoparticulate_mannitol_powders_for_targeted_pulmonary_delivery_as_dry_powder_inhalers_ L2 - https://www.liebertpub.com/doi/full/10.1089/jamp.2013.1078?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -